Jan Henk Coert

Jan Henk Coert

Auto-generated profile, based on publicly available information

Jan Henk Coert

Department of Plastic, Reconstructive and Hand Surgery, University Medical Center Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2018 in Neuro-Oncology Practice
Verified
Journal Article
Open access
PDF file
EMEnrico Martin
Enrico Martin
IMIvo S Muskens
Ivo S Muskens
JCJ H Coert
J H Coert
TSTimothy R Smith
Timothy R Smith
MBMarike L D Broekman
Marike L D Broekman
Currently, literature is scarce on differences across all possible tumor sites in malignant peripheral nerve sheath tumors (MPNSTs). To determine differences in treatment and survival across tumor sites and assess possible predictors for survival, we used the Surveillance, Epidemiology, and End Results (SEER) database. MPNST cases were obtained from the SEER database. Tumor sites were recoded into: intracranial, spinal, head and neck (H&N), limbs, core (thorax/abdomen/pelvis), and unknown site of origin. Patient and tumor characteristics, treatment modalities, and survival were extracted. Overall survival (OS) was assessed using univariable and multivariable Cox regression hazard models. Kaplan-Meier survival curves were constructed per tumor site for OS and disease-specific survival (DSS). A total of 3267 MPNST patients were registered from 1973 to 2013; 167 intracranial (5.1%), 119 spinal (3.6%), 449 H&N (13.7%), 1022 limb (31.3%), 1307 core (40.0%), and 203 unknown (6.2%). The largest tumors were found in core sites (80.0 mm, interquartile range [IQR]: 60.0-115.0 mm) and the smallest were intracranial (37.4 mm, IQR: 17.3-43.5 mm). Intracranial tumors were least frequently resected (58.1%), whereas spinal tumors were most often resected (83.0%). Radiation was administered in 35.5% to 41.8%. Independent factors associated with decreased survival were: older age, male sex, black race, no surgery, partial resection, large tumor size, high tumor grade, H&N site, and core site (all P < .05). Intracranial and pediatric tumors show superior survival (both P < .05). Intracranial tumors show superior OS and DSS curves, whereas core tumors have the worst (P < .001). Superior survival is seen in intracranial and pediatric MPNSTs. Core and H&N tumors have a worse prognosis.

3 June 2020 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
EMEnrico Martin
Enrico Martin
UFUta E. Flucke
Uta E. Flucke
JCJ. Henk Coert
J. Henk Coert
MNMax M. Van Noesel
Max M. Van Noesel
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are rare yet highly aggressive soft tissue sarcomas. Children with neurofibromatosis type 1 (NF1) have a 10% lifetime risk for development of MPNST. Prognosis remains poor and survival seems worse for NF1 patients.Methods: This narrative review highlights current practices and pitfalls in the management of MPNST in pediatric NF1 patients.Results: Preoperative diagnostics can be challenging, but PET scans have shown to be useful tools. More recently, functional MRI holds promise as well. Surgery remains the mainstay treatment for these patients, but careful planning is needed to minimize postoperative morbidity. Functional reconstructions can play a role in improving functional status. Radiotherapy can be administered to enhance local control in selected cases, but care should be taken to minimize radiation effects as well as reduce the risk of secondary malignancies. The exact role of chemotherapy has yet to be determined. Reports on the efficacy of chemotherapy vary as some report lower effects in NF1 populations. Promisingly, survival seems to ameliorate in the last few decades and response rates of chemotherapy may increase in NF1 populations when administering it as part of standard of care. However, in metastasized disease, response rates remain poor. New systemic therapies are therefore desperately warranted and multiple trials are currently investigating the role of drugs. Targeted drugs are nevertheless not yet included in first line treatment.Conclusion: Both research and clinical efforts benefit from multidisciplinary approaches with international collaborations in this rare malignancy.

2 March 2013 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
MSMichael S. Saltzherr
Michael S. Saltzherr
JNJohan W. van Neck
Johan W. van Neck
GMGalied S. R. Muradin
Galied S. R. Muradin
RORody Ouwendijk
Rody Ouwendijk
JLJolanda J. Luime
Jolanda J. Luime
RSRuud Selles
Ruud Selles

1 April 2020 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
EMEnrico Martin
Enrico Martin
MDMax J. Dullaart
Max J. Dullaart
CVCornelis Verhoef
Cornelis Verhoef
JCJ. Henk Coert
J. Henk Coert

1 October 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
EMEnrico Martin
Enrico Martin
MDMax J. Dullaart
Max J. Dullaart
MSMichiel A.J. van de Sande
Michiel A.J. van de Sande
WHWinan J. van Houdt
Winan J. van Houdt
PSPascal P.A. Schellekens
Pascal P.A. Schellekens
JCJ. Henk Coert
J. Henk Coert

1 January 2019 in JBJS Reviews
Verified
Journal Article
Closed access
SWSuzanne C. Wilkens
Suzanne C. Wilkens
MMMichael M. Meghpara
Michael M. Meghpara
DRDavid Ring
David Ring
JCJ. Henk Coert
J. Henk Coert
JJJesse B. Jupiter
Jesse B. Jupiter
NCNeal C. Chen
Neal C. Chen
* Trapeziometacarpal arthrosis is an expected part of normal human aging. * The radiographic severity of trapeziometacarpal arthrosis may not correlate with symptom intensity or magnitude of limitations. * Psychosocial factors may be important drivers of symptom intensity, magnitude of limitations, and seeking of treatment. * Nonoperative treatment is palliative and not disease-modifying, but may facilitate long-term adaptation. * Current surgical treatment strategies center around trapeziectomy, but it is unclear whether the addition of other stabilization or interposition techniques changes overall outcomes.